Proving the clinical applicability of this concept, the dual agonist Tirzepatide (TZP), a GIP/GLP-1 analog that shows higher affinity to GIPR than to GLP-1R, demonstrated safety and efficacy by improving glycemic control and weight management in a clinical trial program for T2D [100]. This evidence concerns the gene GCG and type 2 diabetes mellitus.